Mandate

Vinge advises Cellink in conjunction with the acquisition of cytena

August 05, 2019 M&A

Vinge has advised Cellink AB (publ) in connection with the acquisition of all shares in cytena GmbH. cytena is a life science company which focuses on single cell technologies.

Cytena was established in 2014 from the Institute for Microsystems Technology at the University of Freiburg and primarily sells solutions for the handling of biological cells. The purchase price amounts to MEUR 30.25, corresponding to MSEK 323, and is paid with 1/3 in cash and 2/3 in newly issued Cellink shares. Cellink will convene an extraordinary general meeting which will resolve upon the directed issue of shares to the sellers of cytena.

Vinge’s team primarily consisted of Anders Strid, Daniel Lennartsson Anderås, Alexander Lindeberg and Adam Loewenstein.

Related

Vinge has advised HealthCap on the establishment of HealthCap IX

HealthCap IX has held its final closing, raising total commitments in excess of the target from a diverse investor base comprising established institutions, pension funds, and renowned investors within the life sciences sector. The strong support reflects continued confidence in HealthCap’s strategy and proven track record.
August 22, 2025

Vinge advises MAAG Gear with its MEUR 18.5 refinancing

Vinge has advised MAAG Gear in connection with entering into a EUR 18 500 000 facility agreement with Danske Bank A/S for the purpose of, among other things, refinancing its previous credit. MAAG Gear is a leading manufacturer of industrial gear solutions for cement and mining applications with a comprehensive product portfolio and global aftermarket services offering.
August 21, 2025

Vinge has advised Direktronik in conjunction with the acquisition of Qvintus

Direktronik, a subsidiary of Lagercrantz Group, has acquired all shares in Qvintus.
August 19, 2025